Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target.
glypican-1
personalized dosimetry
radioimmunotherapy
solid tumors
theranostic
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
12
2020
accepted:
17
05
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Radioimmunotherapy (i.e., the use of radiolabeled tumor targeting antibodies) is an emerging approach for the diagnosis, therapy, and monitoring of solid tumors. Often using paired agents, each targeting the same tumor molecule, but labelled with an imaging or therapeutic isotope, radioimmunotherapy has achieved promising clinical results in relatively radio-resistant solid tumors such as prostate. Several approaches to optimize therapeutic efficacy, such as dose fractionation and personalized dosimetry, have seen clinical success. The clinical use and optimization of a radioimmunotherapy approach is, in part, influenced by the targeted tumor antigen, several of which have been proposed for different solid tumors. Glypican-1 (GPC-1) is a heparan sulfate proteoglycan that is expressed in a variety of solid tumors, but whose expression is restricted in normal adult tissue. Here, we discuss the preclinical and clinical evidence for the potential of GPC-1 as a radioimmunotherapy target. We describe the current treatment paradigm for several solid tumors expressing GPC-1 and suggest the potential clinical utility of a GPC-1 directed radioimmunotherapy for these tumors.
Identifiants
pubmed: 34646364
doi: 10.1177/17588359211022918
pii: 10.1177_17588359211022918
pmc: PMC8504276
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359211022918Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: Authors MEL, DHC and BJW are employees and shareholders of GlyTherix Ltd.
Références
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28316-28327
pubmed: 33106429
Cancer Immunol Immunother. 2004 Nov;53(11):995-1004
pubmed: 15449043
Nucl Med Biol. 2007 Oct;34(7):757-78
pubmed: 17921028
Elife. 2020 Mar 31;9:
pubmed: 32228854
Target Oncol. 2018 Apr;13(2):189-203
pubmed: 29423595
Nat Rev Cancer. 2015 Jun;15(6):347-60
pubmed: 25998714
J Cancer Res Ther. 2014 Jan-Mar;10(1):112-20
pubmed: 24762497
Nat Biotechnol. 2019 May;37(5):523-526
pubmed: 30936563
Q J Nucl Med Mol Imaging. 2017 Jun;61(2):168-180
pubmed: 28217987
Front Neurol. 2018 Jan 15;8:748
pubmed: 29379468
Eur Urol. 2016 May;69(5):767-70
pubmed: 26706103
Cell Biophys. 1993 Jan-Jun;22(1-3):27-47
pubmed: 7889541
J Surg Oncol. 2014 Apr;109(5):451-8
pubmed: 24249594
Mod Pathol. 2018 May;31(5):809-815
pubmed: 29327712
Urol Oncol. 2020 Nov;38(11):848.e9-848.e16
pubmed: 32600929
Oncotarget. 2017 Apr 11;8(15):24741-24752
pubmed: 28445969
Mol Pharm. 2014 Nov 3;11(11):3988-95
pubmed: 25058168
Clin Cancer Res. 2020 Nov 15;26(22):5830-5842
pubmed: 32816889
J Nucl Med. 2010 Aug;51(8):1293-300
pubmed: 20660376
Int J Cancer. 2018 Mar 1;142(5):1056-1066
pubmed: 29055044
Nucl Med Commun. 1989 May;10(5):345-52
pubmed: 2662074
J Clin Invest. 2008 Jan;118(1):89-99
pubmed: 18064304
Cancer Biother Radiopharm. 2017 Sep;32(7):258-265
pubmed: 28910150
Int J Cancer. 2017 Feb 15;140(4):938-947
pubmed: 27813061
Cancer Med. 2017 Jun;6(6):1181-1191
pubmed: 28440066
J Urol. 1989 Dec;142(6):1578-83
pubmed: 2685375
World Neurosurg. 2017 Sep;105:282-288
pubmed: 28602885
J Clin Oncol. 2007 Dec 1;25(34):5465-70
pubmed: 18048828
J Clin Oncol. 2004 Aug 1;22(15):3003-15
pubmed: 15210739
Oncotarget. 2015 Oct 6;6(30):30384-93
pubmed: 26309164
Oncologist. 2017 Dec;22(12):1470-1477
pubmed: 29146617
Asian J Surg. 2013 Jan;36(1):7-12
pubmed: 23270819
Biochem Biophys Res Commun. 2004 Aug 6;320(4):1148-55
pubmed: 15249209
Oncotarget. 2016 Jun 21;7(25):38835-38844
pubmed: 27246980
J Nucl Med. 2019 Aug;60(8):1073-1079
pubmed: 30683761
Cancer Res. 2003 Aug 15;63(16):5084-90
pubmed: 12941838
Urol Res. 1991;19(4):207-13
pubmed: 1926654
Transl Oncol. 2019 Nov;12(11):1395-1403
pubmed: 31400579
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7195s-7200s
pubmed: 16203821
Adv Exp Med Biol. 2020;1245:163-176
pubmed: 32266658
Cancer Manag Res. 2017 Dec 29;10:13-21
pubmed: 29343986
Cancer. 2012 Nov 15;118(22):5497-506
pubmed: 22569804
Nucl Med Biol. 2006 Nov;33(8):991-8
pubmed: 17127172
J Clin Oncol. 2020 Dec 20;38(36):4283-4291
pubmed: 33119478
Theranostics. 2014 Apr 25;4(7):708-20
pubmed: 24883121
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Front Immunol. 2019 Mar 28;10:603
pubmed: 30984182
Clin Cancer Res. 2007 Mar 1;13(5):1374-82
pubmed: 17309914
N Engl J Med. 1983 Oct 20;309(16):937-41
pubmed: 6621620
Front Pharmacol. 2015 Mar 31;6:54
pubmed: 25873896
J Med Radiat Sci. 2017 Mar;64(1):52-60
pubmed: 28303694
J Clin Oncol. 2005 Jul 20;23(21):4591-601
pubmed: 15837970
Nucl Med Mol Imaging. 2019 Dec;53(6):374-381
pubmed: 31867072
Clin Cancer Res. 2013 Sep 15;19(18):5182-91
pubmed: 23714732
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Front Oncol. 2019 Jul 12;9:614
pubmed: 31355137
Asia Ocean J Nucl Med Biol. 2021 Spring;9(2):86-100
pubmed: 34250138
PLoS One. 2013 Jul 29;8(7):e69613
pubmed: 23922757
J Clin Invest. 1998 Nov 1;102(9):1662-73
pubmed: 9802880
J Nucl Med. 2020 Aug;61(8):1205-1211
pubmed: 32169921
Tumour Biol. 2015 Jun;36(6):4053-62
pubmed: 25926382
Cancer Immunol Immunother. 2004 Jun;53(6):533-42
pubmed: 14722669
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92
pubmed: 24577951
J Labelled Comp Radiopharm. 2018 Jul;61(9):715-726
pubmed: 29524233
Biomol Ther (Seoul). 2015 Nov;23(6):493-509
pubmed: 26535074
Nat Commun. 2018 Apr 24;9(1):1629
pubmed: 29691406
J Nucl Med. 2019 Jun;60(6):777-785
pubmed: 30442752
Br J Cancer. 2019 Jul;121(1):5-14
pubmed: 31110329
EJNMMI Res. 2020 May 7;10(1):46
pubmed: 32382920
Dev Dyn. 1998 Jan;211(1):72-87
pubmed: 9438425
Neural Dev. 2009 Sep 04;4:33
pubmed: 19732411
J Nucl Med. 2015 Feb;56(2):249-54
pubmed: 25613538
BMC Cancer. 2015 Oct 20;15:742
pubmed: 26482785
Dig Dis Sci. 2019 Jun;64(6):1493-1502
pubmed: 30730015
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
BMC Cancer. 2018 Jun 8;18(1):646
pubmed: 29884132
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
Biochem Pharmacol. 2019 Oct;168:108-118
pubmed: 31251939
J Med Chem. 2014 Mar 27;57(6):2657-69
pubmed: 24533799
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1233-1241
pubmed: 29470615
Cancer Res. 2001 Jul 15;61(14):5562-9
pubmed: 11454708
Oncotarget. 2018 Apr 10;9(27):19006-19013
pubmed: 29721179
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):352-360
pubmed: 28440324
Br J Cancer. 2016 Jun 28;115(1):66-75
pubmed: 27310703
Clin Cancer Res. 2009 Feb 1;15(3):865-75
pubmed: 19188157
Theranostics. 2019 Jun 9;9(15):4409-4420
pubmed: 31285769
J Nucl Med. 2016 Oct;57(10):1576-1582
pubmed: 27127217
Oncogene. 2012 May 17;31(20):2535-44
pubmed: 21996748
Cancer. 2002 Feb 15;94(4 Suppl):1332-48
pubmed: 11877764
Theranostics. 2020 Sep 14;10(25):11359-11375
pubmed: 33052220
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Cancer. 2019 Aug 1;125(15):2561-2569
pubmed: 31012963
J Nucl Med. 2008 Jul;49(7):1066-74
pubmed: 18552139
MAbs. 2010 Nov-Dec;2(6):682-94
pubmed: 20935511
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
J Nucl Med. 2018 Jan;59(1):161-166
pubmed: 28637800
Bioconjug Chem. 2021 Jan 20;32(1):25-42
pubmed: 33325685
Pharmaceuticals (Basel). 2011 Dec 22;5(1):1-15
pubmed: 22229017
Cancer Res. 1990 Feb 1;50(3 Suppl):846s-851s
pubmed: 2297732
Pharmaceuticals (Basel). 2012 Jan 05;5(1):79-93
pubmed: 24288044
J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S
pubmed: 15653670
Int J Cancer. 2002 Oct 20;101(6):567-75
pubmed: 12237899
Am J Pathol. 2006 Jun;168(6):2014-26
pubmed: 16723715
Nucl Med Biol. 2011 Aug;38(6):849-55
pubmed: 21843781
Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):819-23
pubmed: 23463331
Asian Pac J Cancer Prev. 2015;16(17):7441-7
pubmed: 26625741
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588
pubmed: 28653357
Curr Oncol. 2018 Oct;25(5):e373-e384
pubmed: 30464687
J Nucl Med. 2021 Aug 1;62(8):1097-1105
pubmed: 33277400
Lancet Oncol. 2018 Aug;19(8):e373
pubmed: 30102223
Int J Oncol. 2006 Nov;29(5):1139-48
pubmed: 17016645
Cancer Lett. 2017 May 1;393:86-93
pubmed: 28232049
Toxicol Appl Pharmacol. 2013 Dec 1;273(2):298-313
pubmed: 24035823
J Cancer. 2016 May 21;7(8):1002-9
pubmed: 27313791